CAMBRIDGE, Mass. — Vyome Holdings Inc. reported first-quarter 2026 financial results and said it has advanced key regulatory and business development initiatives tied to its pipeline for immuno-inflammatory and rare disease conditions.
The Cambridge-based clinical-stage biopharmaceutical company said it submitted materials to the U.S. Food and Drug Administration related to VT-1953, including an application for orphan drug designation and proposals seeking FDA guidance on the next stages of development. Vyome is developing VT-1953 for malignant fungating wounds, a condition the company said has no FDA-approved therapies specifically addressing it.
Vyome also said it signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets. The company said the deal gives it access to a global market estimated at about $57 billion.
Krishna Gupta, chairman of Vyome, said the company has executed with focus and discipline over the last several quarters while advancing programs in areas of significant unmet medical need.
“Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on inflammatory disorders. Inflammation remains one of the world’s largest problems, and we believe Vyome is well positioned for long-term value creation. We continue to strengthen our scientific, operational, and governance foundation while remaining highly disciplined on capital structure and shareholder alignment,” Gupta said.
CEO Venkat Nelabhotla said Vyome is moving VT-1953 toward pivotal-stage readiness while continuing regulatory, manufacturing and development work.
“We continue to advance VT-1953 toward pivotal-stage readiness while maintaining a strong focus on disciplined execution, regulatory engagement, manufacturing preparedness, and financial stewardship. We submitted to the FDA an application for the approval of orphan drug designation status and proposals across several areas of the next stages of development readiness, and continue to believe VT-1953 addresses a major unmet need in malignant fungating wounds, where there are currently no FDA-approved therapies specifically addressing the condition,” Nelabhotla said.
“Importantly, we have continued to preserve what we believe is one of the Company’s key differentiators: a clean and disciplined capital structure with no debt, no preferred stock, and no toxic financing instruments. We remain focused on creating long-term shareholder value while advancing our immuno-inflammatory and rare disease strategy,” he said.
During the quarter, Vyome raised about $5.29 million in gross proceeds through the sale of 1,089,545 common shares on Jan. 27, 2026, at an average price of $5 per share. The company said the price represented a 59.2% premium to the prior day’s closing price and resulted in about 15% dilution to existing shareholders.
Vyome also said it continued scientific and translational work supporting VT-1908 and its broader immuno-inflammatory programs. The company presented positive Phase 2 clinical data for VT-1953 at the American Association for Cancer Research 2026 meeting.
For the quarter ended March 31, Vyome reported cash and cash equivalents of about $8.8 million, up from about $5 million at the end of 2025. Total assets were about $10.2 million, and total stockholders’ equity was about $8 million.
Operating expenses for the quarter totaled about $1.1 million, including about $666,000 in research and development expenses and about $478,000 in selling, general and administrative expenses. Net loss attributable to common shareholders was about $963,000, or 15 cents per basic and diluted share.
